Search

Your search keyword '"Wagner, Andrew J."' showing total 139 results
Start Over Author "Wagner, Andrew J." Publisher american association for cancer research (aacr)
139 results on '"Wagner, Andrew J."'

1. Safety And Efficacy Of Combination Lurbinectedin Plus Doxorubicin From A Phase 1b Trial In Patients With Advanced/Metastatic Soft Tissue Sarcoma

Author

Cote, Gregory M., primary, Haddox, Candace L., additional, Choy, Edwin, additional, Merriam, Priscilla A., additional, Mazzola, Emanuele, additional, Venkataraman, Vinayak, additional, Alcindor, Thierry, additional, Wagner, Andrew J., additional, Demetri, George D., additional, and George, Suzanne, additional

Published
2024
Full Text
View/download PDF

2. Supplementary Table 4 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

3. Supplementary Figure 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Table 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

6. Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Material 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Table 3 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

10. Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Material 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Figure 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Table 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

14. Supplementary Table 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Table 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Table 3 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Table 4 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

20. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., additional, Mazzola, Emanuele, additional, Lin, Jia-Ren, additional, Baginska, Joanna, additional, Nau, Allison, additional, Weirather, Jason L., additional, Choy, Edwin, additional, Marino-Enriquez, Adrian, additional, Morgan, Jeffrey A., additional, Cote, Gregory M., additional, Merriam, Priscilla, additional, Wagner, Andrew J., additional, Sorger, Peter K., additional, Santagata, Sandro, additional, and George, Suzanne, additional

Published
2024
Full Text
View/download PDF

21. Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

22. Table S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

23. Table S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

24. Table S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

25. Figure S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

26. Data from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

27. Figure S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

28. Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

29. Table S4 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

30. Table S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

31. Figure S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

32. Figure S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

33. Table S4 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

34. Data from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

35. Table S4 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

36. Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

37. Figure S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

38. Table S4 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

39. Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

40. Table S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

41. Figure S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

42. Figure S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

43. Data from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

44. Figure S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

45. Table S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

46. Table S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

47. Table S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

48. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, additional, Wagner, Andrew J., additional, Burgess, Melissa A., additional, Junker, Niels, additional, Chisamore, Michael, additional, Peterson, Patrick, additional, Szpurka, Anna M., additional, Ceccarelli, Matteo, additional, and Tap, William D., additional

Published
2023
Full Text
View/download PDF

49. Abstract LB288: Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations

Author

Cranmer, Lee D., primary, Wagner, Andrew J., additional, Ravi, Vinod, additional, Riedel, Richard F., additional, Ganjoo, Kristen N., additional, Van Tine, Brian A., additional, Chugh, Rashmi, additional, Gordon, Erlinda M., additional, Kwiatkowski, David J., additional, Hornick, Jason L., additional, Du, Heng, additional, Ding, Li, additional, Schmid, Anita N., additional, Navarro, Willis H., additional, Itri, Loretta M., additional, and Dickson, Mark A., additional

Published
2023
Full Text
View/download PDF

50. Data Supplement from Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

Author

Zhang, Yi-Xiang, primary, Sicinska, Ewa, primary, Czaplinski, Jeffrey T., primary, Remillard, Stephen P., primary, Moss, Samuel, primary, Wang, Yuchuan, primary, Brain, Christopher, primary, Loo, Alice, primary, Snyder, Eric L., primary, Demetri, George D., primary, Kim, Sunkyu, primary, Kung, Andrew L., primary, and Wagner, Andrew J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results